(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are VerifyMe, Evofem Biosciences, and Zai Lab.

Rank Financial Asset Price Change Updated (EST)
1 VerifyMe (VRME) 2.39 21.94% 2022-07-01 14:53:32
2 Evofem Biosciences (EVFM) 1.13 15.24% 2022-06-30 23:47:15
3 Zai Lab (ZLAB) 38.74 11.69% 2022-07-01 14:55:42
4 Novavax (NVAX) 57.02 10.87% 2022-07-01 14:58:35
5 Edesa Biotech (EDSA) 1.61 10.27% 2022-06-30 19:49:14
6 Equillium (EQ) 2.04 9.09% 2022-06-30 22:23:13
7 Inovio Pharmaceuticals (INO) 1.89 8.96% 2022-07-01 14:57:13
8 Etsy (ETSY) 79.75 8.93% 2022-07-01 14:59:20
9 Redfin (RDFN) 8.94 8.43% 2022-07-01 14:45:37
10 FibroGen (FGEN) 11.42 8.14% 2022-07-01 14:55:51

The three most active and biggest losers today are Entera Bio Ltd., Esports Entertainment Group, and Whole Earth Brands.

Rank Financial Asset Price Change Updated (EST)
1 Entera Bio Ltd. (ENTXW) 0.06 -38.46% 2022-06-30 21:14:05
2 Esports Entertainment Group (GMBLW) 0.10 -35.54% 2022-07-01 13:41:15
3 Whole Earth Brands (FREEW) 0.28 -20% 2022-07-01 07:23:11
4 Greenrose Acquisition Corp. (GNRS) 2.03 -19.44% 2022-07-01 15:07:07
5 Enochian Biosciences (ENOB) 1.93 -18.57% 2022-06-30 21:12:06
6 Full House Resorts (FLL) 5.19 -14.64% 2022-07-01 14:56:07
7 East Stone Acquisition Corporation (ESSCR) 0.14 -12.5% 2022-06-30 23:11:06
8 ESSA Pharma (EPIX) 3.15 -9.48% 2022-06-30 21:23:14
9 Amkor Technology (AMKR) 15.36 -9.35% 2022-07-01 14:53:21
10 Dell (DELL) 42.56 -7.89% 2022-07-01 14:53:41

Most Active Winners today

1. VerifyMe (VRME) – 21.94%

VerifyMe, Inc. offers security solutions to identify and authenticate people, products, or packaging in various areas of the United States. RainbowSecure is a combination of an invisible ink and a tuned laser that allows counterfeit products to be exposed. SecureLight technology changes the color to suit various applications such as credit cards and driver’s licences. It also offers SecureLight+ technology which can authenticate products with both proprietary tuned lasers and fluorescent lighting. VeriPAS technology is also offered by the company. This technology provides brand owners with geographical information on counterfeiting. VeriPAS Smartphone Authenticator technology scans invisible RainbowSecure code labels. VerifyMe as Authentic Technology, a pre-printed dual-purpose label that includes a QR code visible for consumers scanning and an invisible serialized IR Code for inspection scanning and authentication. VerifyMe Beeper technology provides instant authentication for items such as tickets for events at a gate. VerifyMe, Inc. is a strategic partner with INX International Ink Company and Techind Engineers & Consultants -Impex. The original name of the company was LaserLock Technologies, Inc., but it changed its name in July 2015 to VerifyMe, Inc. VerifyMe, Inc. is an American company that was established in 1999. Its headquarters are in Rochester, New York.

NASDAQ ended the session with VerifyMe jumping 21.94% to $2.39 on Friday, after three sequential sessions in a row of losses. NASDAQ rose 0.9% to $11,127.84, after four sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Volume

Today’s last reported volume for VerifyMe is 9596280 which is 44085.8% above its average volume of 21718.

VerifyMe’s last close was $1.96, 55.92% below its 52-week high of $4.45.

VerifyMe’s Sales

VerifyMe’s sales growth is 400% for the ongoing quarter and 233.3% for the next. The company’s growth estimates for the present quarter is 38.9% and a drop 107.4% for the next.

VerifyMe’s Revenue

Year-on-year quarterly revenue growth grew by 240%, now sitting on 867k for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

VerifyMe’s stock is considered to be overbought (>=80).

VerifyMe’s Stock Yearly Top and Bottom Value

VerifyMe’s stock is valued at $2.39 at 17:32 EST, way below its 52-week high of $4.45 and way higher than its 52-week low of $2.05.

VerifyMe’s Moving Average

VerifyMe’s value is way under its 50-day moving average of $2.67 and way below its 200-day moving average of $3.16.

More news about VerifyMe.

2. Evofem Biosciences (EVFM) – 15.24%

Evofem Biosciences, Inc., is a biopharmaceutical firm that develops and markets products for women’s reproductive and sexual health. Phexxi is a vaginal cream for prevention of pregnancies. EVO100 is an antimicrobial vaginal cream that prevents urinary transmission of Chlamydia Trachomatis and Neisseria Gonorrhoeae infections in women. To educate the oncology community regarding Phexxi, it has entered into a partnership agreement with National Community Oncology Dispensing Association, Inc. Evofem Biosciences, Inc., is located in San Diego, California.

NASDAQ ended the session with Evofem Biosciences jumping 15.24% to $1.13 on Friday, following the last session’s upward trend. NASDAQ jumped 0.9% to $11,127.84, after four successive sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for Evofem Biosciences is 119080000 which is 460.96% above its average volume of 21227600.

Evofem Biosciences’s last close was $1.13, 93.15% under its 52-week high of $16.50.

Evofem Biosciences’s Sales

Evofem Biosciences’s sales growth is 160.8% for the current quarter and 300.1% for the next. The company’s growth estimates for the present quarter and the next is 64.3% and 34.6%, respectively.

Evofem Biosciences’s Revenue

Year-on-year quarterly revenue growth grew by 2025%, now sitting on 8.24M for the twelve trailing months.

Evofem Biosciences’s Stock Yearly Top and Bottom Value

Evofem Biosciences’s stock is valued at $1.13 at 17:32 EST, way below its 52-week high of $16.50 and way higher than its 52-week low of $0.28.

Evofem Biosciences’s Moving Average

Evofem Biosciences’s worth is higher than its 50-day moving average of $1.12 and way under its 200-day moving average of $5.88.

More news about Evofem Biosciences.

3. Zai Lab (ZLAB) – 11.69%

Zai Lab Limited is a biopharmaceutical firm that focuses on developing and licensing therapeutics for medical use in China. Niraparib is an oral small-molecule poly ADPribose Polymerase 1/2 inhibitor that can be used to treat multiple solid tumors such as ovarian or other forms of lung cancer. Optune is a treatment for glioblastoma multiforme. Ripretinib is a switch inhibitor that can be used to treat KIT- and/or PDGFRa driven cancers. It also produces REGN1979, which treats diffuse large B cell lymphoma, and follicular Lymphoma. Margetuximab, an immuno-optimized monoclonal anti-HER2 antibody, for treatment of breast cancer and gastric cancers. INCMGA0012, a monoclonal investigational antibody, for treatment MSI-highendometrial carcinoma. Bemarituzumab is a monoclonal humanized antibody that can be used to treat gastric or gastroesophageal carcinomas. Omadacycline and Durlobactam are antibiotics for treating acinetobacter and baumannii bacteria infections. Zai Lab Limited is a licensee and has a collaboration agreement with Paratek Bermuda, Ltd., TESARO Inc., Entasis Therapeutics Holdings, Inc., Crescendo Biologics Ltd., Novocure Limited, MacroGenics Inc., Deciphera Pharmaceuticals, LLC, and Incyte Corporation. China’s Shanghai is the headquarters of this company, which was established in 2013.

NASDAQ ended the session with Zai Lab rising 11.69% to $38.74 on Friday, after five successive sessions in a row of gains. NASDAQ jumped 0.9% to $11,127.84, after four consecutive sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for Zai Lab is 539926 which is 13.96% below its average volume of 627601.

Zai Lab’s last close was $34.68, 80.62% under its 52-week high of $178.91.

Zai Lab’s Sales

Zai Lab’s sales growth is 54.1% for the current quarter and 55.7% for the next. The company’s growth estimates for the ongoing quarter and the next is 65.5% and 39.2%, respectively.

Zai Lab’s Revenue

Year-on-year quarterly revenue growth grew by 192.6%, now sitting on 144.31M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Zai Lab’s stock is considered to be oversold (<=20).

Zai Lab’s Stock Yearly Top and Bottom Value

Zai Lab’s stock is valued at $38.74 at 17:32 EST, way under its 52-week high of $178.91 and way above its 52-week low of $22.51.

Zai Lab’s Moving Average

Zai Lab’s worth is way higher than its 50-day moving average of $33.65 and way under its 200-day moving average of $62.15.

More news about Zai Lab.

4. Novavax (NVAX) – 10.87%

Novavax, Inc., along with Novavax AB, a subsidiary, focuses on developing, commercializing and marketing vaccines that prevent serious infections. ResVax is a candidate for a vaccine against respiratory syncytial viruses (RSV), fusion (F), protein nanoparticles. It’s currently in Phase III clinical trials to prevent RSV infection in infants through maternal immunization. NanoFlu is also in Phase III clinical trials and can be used to treat seasonal influenza in elderly adults. Matrix-M is the company’s main adjuvant. It is used to increase the immune system attack against microorganisms and to immunize with lower levels of antigen. RSV F vaccine is being developed by the company for elderly (60+) and healthy children (6 months to 5 years old). Phase II clinical trials are ongoing. Phase I clinical trials are underway for both. It is also developing nanoparticle vaccine candidates to be used in clinic testing for the ebola virus. The company also has a COVID-19 vaccine being developed for the coronavirus, which causes symptoms similar to pneumonia. This is currently in preclinical phase. Novavax, Inc., was established in 1987. It is located in Gaithersburg, Maryland.

NASDAQ ended the session with Novavax jumping 10.87% to $57.02 on Friday while NASDAQ jumped 0.9% to $11,127.84.

Volume

Today’s last reported volume for Novavax is 6036200 which is 1.81% below its average volume of 6147520.

Novavax’s last close was $51.43, 81.49% under its 52-week high of $277.80.

The company’s growth estimates for the present quarter and the next is 210.7% and 254.1%, respectively.

Novavax’s Revenue

Year-on-year quarterly revenue growth declined by 20.5%, now sitting on 1.15B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Novavax’s stock is considered to be overbought (>=80).

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $57.02 at 17:32 EST, way under its 52-week high of $277.80 and way above its 52-week low of $34.88.

Novavax’s Moving Average

Novavax’s worth is way higher than its 50-day moving average of $49.72 and way under its 200-day moving average of $116.21.

More news about Novavax.

5. Edesa Biotech (EDSA) – 10.27%

Edesa Biotech, Inc. is a biopharmaceutical company at the clinical stage. It specializes in developing, manufacturing, and marketing pharmaceutical products to treat inflammatory and immune-related disorders. The company’s leading product candidates include EB05 (a monoclonal anti-inflammatory antibody) which is currently in Phase 2/Phase3 clinical trial for acute respiratory distress syndrome treatment in patients with covid-19. EB01 is a non-steroidal anti-inflammatory cream that is currently in Phase 2B clinical trials to treat chronic allergic contacts dermatitis. The company is also developing EB02 and EB06 monoclonal antibodies candidates. NovImmune SA has entered into a partnership agreement to create monoclonal antibodies that target products containing toll like receptor 4 or chemokine.ligand 10, for diagnostic, therapeutic and prophylactic applications in animals and humans. Yissum Research Development Company is responsible for developing products for topical, dermal, dermatologic, and other gastrointestinal applications. Edesa Biotech, Inc., was established in 2015. It is located in Markham, Canada.

NASDAQ ended the session with Edesa Biotech jumping 10.27% to $1.61 on Friday while NASDAQ rose 0.9% to $11,127.84.

Volume

Today’s last reported volume for Edesa Biotech is 116273 which is 98.34% above its average volume of 58622.

Edesa Biotech’s last close was $1.61, 86.58% under its 52-week high of $12.00.

The company’s growth estimates for the present quarter is a negative 94.7% and positive 2.8% for the next.

Edesa Biotech’s Stock Yearly Top and Bottom Value

Edesa Biotech’s stock is valued at $1.61 at 17:32 EST, way below its 52-week high of $12.00 and way higher than its 52-week low of $1.30.

Edesa Biotech’s Moving Average

Edesa Biotech’s worth is way below its 50-day moving average of $1.96 and way under its 200-day moving average of $4.55.

More news about Edesa Biotech.

6. Equillium (EQ) – 9.09%

Equillium, Inc., is a biotech company at the clinical stage. It develops and markets products that treat serious autoimmune, inflammatory, and immuno-inflammatory conditions. Itolizumab is the company’s principal product candidate. This monoclonal, clinical-stage antibody targets the new immune checkpoint receptor CD6. Phase 1b/2 clinical trials are underway for acute graft-versus host disease. Phase 1b/2 is for asthma. Equillium, Inc. was previously known as Attenuate biopharmaceuticals, Inc. Equillium, Inc., was founded in 2017. It is located in La Jolla, California.

NASDAQ ended the session with Equillium jumping 9.09% to $2.04 on Friday, following the last session’s upward trend. NASDAQ rose 0.9% to $11,127.84, after four sequential sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Volume

Today’s last reported volume for Equillium is 27434 which is 10.63% below its average volume of 30700.

Equillium’s last close was $2.04, 71.35% under its 52-week high of $7.12.

The company’s growth estimates for the current quarter and the next is a negative 25.8% and a negative 2.9%, respectively.

Equillium’s Stock Yearly Top and Bottom Value

Equillium’s stock is valued at $2.04 at 17:32 EST, way under its 52-week high of $7.12 and way above its 52-week low of $1.66.

Equillium’s Moving Average

Equillium’s value is way below its 50-day moving average of $2.36 and way under its 200-day moving average of $4.03.

More news about Equillium.

7. Inovio Pharmaceuticals (INO) – 8.96%

Inovio Pharmaceuticals, Inc. is a biotechnology firm that focuses on developing, commercializing, and marketing DNA medicines. These DNA medicines are used to cure, prevent, or treat diseases such as cancer, human papillomavirus, and other infectious diseases. The SynCon immunotherapy design of Inovio Pharmaceuticals, Inc. can break the immune system’s tolerance for cancerous cells. It also facilitates cross-strain protection from unmatched or matched pathogens. It is currently involved in planning and conducting clinical trials of DNA medicines to treat HPV-related precancers. This includes cervical, vulvar and anal dysplasia, HPV, as well as other HPV disorders such as prostate cancer, HIV, Ebola, Middle East Respiratory syndrome (MERS), Lassa virus, Zika virus, and COVID-19 virus. ApolloBio Corp. or AstraZeneca PLC, Beijing Advaccine Biotechnology Co. and The Bill & Melinda Gates Foundation are its partners and collaborators. To support the investigational DNA vaccine, INO-4800 is being tested in Phase 1 clinical trials for COVID-19. The company has also signed an agreement with Richter-Helm BioLogics GmbH & Co. KG. Plymouth Meeting is the headquarters of this company, which was established in 1979.

NASDAQ ended the session with Inovio Pharmaceuticals rising 8.96% to $1.89 on Friday while NASDAQ jumped 0.9% to $11,127.84.

Volume

Today’s last reported volume for Inovio Pharmaceuticals is 4319840 which is 31.83% below its average volume of 6336900.

Inovio Pharmaceuticals’s last close was $1.73, 82.63% below its 52-week high of $9.96.

Inovio Pharmaceuticals’s Sales

Inovio Pharmaceuticals’s sales growth is 138.1% for the current quarter and a decline by 33% for the next. The company’s growth estimates for the current quarter is 17.9% and a drop 3.4% for the next.

Inovio Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth declined by 85%, now sitting on 1.77M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Inovio Pharmaceuticals’s stock is considered to be overbought (>=80).

Inovio Pharmaceuticals’s Stock Yearly Top and Bottom Value

Inovio Pharmaceuticals’s stock is valued at $1.89 at 17:32 EST, way under its 52-week high of $9.96 and way higher than its 52-week low of $1.38.

Inovio Pharmaceuticals’s Moving Average

Inovio Pharmaceuticals’s value is way under its 50-day moving average of $2.20 and way under its 200-day moving average of $4.61.

More news about Inovio Pharmaceuticals.

8. Etsy (ETSY) – 8.93%

NASDAQ ended the session with Etsy jumping 8.93% to $79.75 on Friday, following the last session’s downward trend. NASDAQ jumped 0.9% to $11,127.84, after four successive sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for Etsy is 5331880 which is 7.85% above its average volume of 4943460.

Etsy’s last close was $73.21, 76.21% below its 52-week high of $307.75.

The company’s growth estimates for the present quarter and the next is a negative 38.2% and a negative 16.1%, respectively.

Etsy’s Revenue

Year-on-year quarterly revenue growth grew by 16.2%, now sitting on 2.33B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Etsy’s stock is considered to be overbought (>=80).

Etsy’s Stock Yearly Top and Bottom Value

Etsy’s stock is valued at $79.75 at 17:32 EST, way under its 52-week high of $307.75 and way higher than its 52-week low of $67.01.

Etsy’s Moving Average

Etsy’s value is under its 50-day moving average of $87.42 and way under its 200-day moving average of $167.38.

More news about Etsy.

9. Redfin (RDFN) – 8.43%

Redfin Corporation is a Canadian real estate broker. Redfin Corporation operates an online marketplace for real estate and offers real estate services. This includes assisting people in buying or selling a home. The company also offers title and settlement services, originates and manages mortgages, and purchases and sells houses. Redfin Corporation was previously known as Appliance Computing, Inc. Redfin Corporation was established in 2002. It is located in Seattle, Washington.

NASDAQ ended the session with Redfin rising 8.43% to $8.94 on Friday, after five sequential sessions in a row of losses. NASDAQ jumped 0.9% to $11,127.84, after four successive sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Volume

Today’s last reported volume for Redfin is 2707400 which is 15.39% below its average volume of 3200110.

Redfin’s last close was $8.24, 87.4% under its 52-week high of $65.38.

The company’s growth estimates for the current quarter and the next is a negative 103.4% and a negative 40%, respectively.

Redfin’s Revenue

Year-on-year quarterly revenue growth grew by 163%, now sitting on 1.92B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Redfin’s stock is considered to be overbought (>=80).

Redfin’s Stock Yearly Top and Bottom Value

Redfin’s stock is valued at $8.94 at 17:32 EST, way under its 52-week high of $65.38 and way higher than its 52-week low of $7.13.

Redfin’s Moving Average

Redfin’s value is way below its 50-day moving average of $10.86 and way under its 200-day moving average of $29.93.

More news about Redfin.

10. FibroGen (FGEN) – 8.14%

FibroGen, Inc., is a biopharmaceutical firm that develops, commercializes, and markets therapeutics for serious unmet medical need. Roxadustat is an oral small-molecule inhibitor of hypoxia induce factor prolylhydroxylases. It’s currently in phase III clinical development. Phase II/III development is underway in China. Pamrevlumab is a monoclonal human antibody that blocks the activity of connective tissues growth factor. It is currently in Phase III clinical trials for treatment of diabetes, idiopathic lung fibrosis and pancreatic cancer. There is also a Phase II trial to treat Duchenne muscular dysfunction. Astellas Pharma Inc., AstraZeneca AB and others have signed collaboration agreements. It was founded in 1993, and has its headquarters in San Francisco.

NASDAQ ended the session with FibroGen jumping 8.14% to $11.42 on Friday while NASDAQ jumped 0.9% to $11,127.84.

Volume

Today’s last reported volume for FibroGen is 418724 which is 57.33% below its average volume of 981378.

FibroGen’s last close was $10.56, 62.88% below its 52-week high of $28.45.

FibroGen’s Sales

FibroGen’s sales growth is a negative 50.2% for the ongoing quarter and a decline by 73.2% for the next. The company’s growth estimates for the ongoing quarter is 35.2% and a drop 251.9% for the next.

FibroGen’s Revenue

Year-on-year quarterly revenue growth declined by 74.5%, now sitting on 235.31M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

FibroGen’s stock is considered to be overbought (>=80).

FibroGen’s Stock Yearly Top and Bottom Value

FibroGen’s stock is valued at $11.42 at 17:33 EST, way below its 52-week high of $28.45 and way above its 52-week low of $7.81.

FibroGen’s Moving Average

FibroGen’s value is way higher than its 50-day moving average of $9.78 and under its 200-day moving average of $12.14.

More news about FibroGen.

Most Active Losers Today

1. Entera Bio Ltd. (ENTXW) – -38.46%

NASDAQ ended the session with Entera Bio Ltd. falling 38.46% to $0.06 on Friday while NASDAQ jumped 0.9% to $11,127.84.

Entera Bio Ltd.’s last close was $0.06, 49.44% below its 52-week high of $0.13.

Entera Bio Ltd.’s Stock Yearly Top and Bottom Value

Entera Bio Ltd.’s stock is valued at $0.06 at 17:33 EST, below its 52-week low of $0.07.

More news about Entera Bio Ltd..

2. Esports Entertainment Group (GMBLW) – -35.54%

NASDAQ ended the session with Esports Entertainment Group falling 35.54% to $0.10 on Friday while NASDAQ jumped 0.9% to $11,127.84.

Esports Entertainment Group’s last close was $0.14, 32.7% higher than its 52-week high of $0.11.

Esports Entertainment Group’s Stock Yearly Top and Bottom Value

Esports Entertainment Group’s stock is valued at $0.10 at 17:33 EST, below its 52-week low of $0.11.

More news about Esports Entertainment Group.

3. Whole Earth Brands (FREEW) – -20%

NASDAQ ended the session with Whole Earth Brands falling 20% to $0.28 on Friday while NASDAQ jumped 0.9% to $11,127.84.

Whole Earth Brands’s last close was $0.28, 0% below its 52-week high of $0.28.

Whole Earth Brands’s Stock Yearly Top and Bottom Value

Whole Earth Brands’s stock is valued at $0.28 at 17:33 EST, under its 52-week low of $0.27.

More news about Whole Earth Brands.

4. Greenrose Acquisition Corp. (GNRS) – -19.44%

Greenrose Acquisition Corp. doesn’t have any significant operations. The company plans to merge, exchange shares, acquire assets, stock buy, recapitalization and reorganize with other businesses. It was founded in Amityville in New York in 2019.

NASDAQ ended the session with Greenrose Acquisition Corp. falling 19.44% to $2.03 on Friday, following the last session’s downward trend. NASDAQ rose 0.9% to $11,127.84, after four consecutive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Volume

Today’s last reported volume for Greenrose Acquisition Corp. is 591 which is 79.68% below its average volume of 2909.

Greenrose Acquisition Corp.’s last close was $2.52, 76.27% below its 52-week high of $10.62.

Greenrose Acquisition Corp.’s Revenue

Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 24.16M for the twelve trailing months.

Greenrose Acquisition Corp.’s Stock Yearly Top and Bottom Value

Greenrose Acquisition Corp.’s stock is valued at $2.03 at 17:33 EST, way below its 52-week high of $10.62 and way above its 52-week low of $1.05.

Greenrose Acquisition Corp.’s Moving Average

Greenrose Acquisition Corp.’s value is below its 50-day moving average of $2.15 and way below its 200-day moving average of $5.11.

More news about Greenrose Acquisition Corp..

5. Enochian Biosciences (ENOB) – -18.57%

Enochian Biosciences, Inc. is a biotechnology company at pre-clinical stages. It focuses on the development and research of biological and pharmaceutical products to treat human immunodeficiency viruses (HIV), Hepatitis B virus, influenza, coronavirus and other diseases. ENOBHV-01 is the company’s leading candidate. It includes ENOBHV-11 for autologous HIV cure treatment, ENOBHV-12 as a preventative HIV vaccination, ENOBHV-12 as a therapeutic HIV vaccine, and ENOBHB-01 which is a coopting HIV polymerase. ENOBDC-11, an off-the-shelf DC vaccine that treats multiple solid tumors; ENOBDC-21, which is a vaccine non-specific for intramurmoral injections. Enochian Biosciences, Inc. is a strategic partner of The Scripps Institute, Fred Hutchinson Cancer Research Center, Texas Biomed Research Institute, University of California, Los Angeles, The Hepatitis B Foundation, and Baruch St. Blumberg Institute. Los Angeles is the headquarters of Enochian Biosciences, Inc. which was founded in 2017.

NASDAQ ended the session with Enochian Biosciences sliding 18.57% to $1.93 on Friday while NASDAQ rose 0.9% to $11,127.84.

Volume

Today’s last reported volume for Enochian Biosciences is 1227480 which is 149.52% above its average volume of 491926.

Enochian Biosciences’s last close was $1.93, 85.99% under its 52-week high of $13.78.

Enochian Biosciences’s Stock Yearly Top and Bottom Value

Enochian Biosciences’s stock is valued at $1.93 at 17:33 EST, way under its 52-week high of $13.78 and higher than its 52-week low of $1.88.

Enochian Biosciences’s Moving Average

Enochian Biosciences’s value is way below its 50-day moving average of $5.18 and way under its 200-day moving average of $7.17.

More news about Enochian Biosciences.

6. Full House Resorts (FLL) – -14.64%

Full House Resorts, Inc. develops, owns, manages, leases, invests, and operates casinos and other entertainment and hospitality facilities throughout the United States. Silver Slipper Casino & Hotel is located in Hancock County Mississippi. It has 855 slots and 24 table game options. There’s also a surface parking lot and approximately 800-space garage. The hotel features a fine dining restaurant and buffet as well as a fast-service restaurant and quick-service restaurant. A 37-space beachfront park can be found. Bronco Billy’s Casino and Hotel is also owned and operated in Cripple Creek. It has 36 rooms and various acres worth of surface parking. There are 1 steakhouse, 4 casual restaurants, and gaming space. The Rising Star Casino Resort is also owned and operated by the company. It has 825 slots and 24 table game options. A land-based pavilion that spans approximately 30,000 feet offers meeting space and convention space. There are 190 rooms, a 56-space RV Park, surface parking, and an 18-hole course covering approximately 311 acres. 5 restaurants and a leased hotel with 104 rooms. It also owns the Stockman’s Casino, located in Fallon in Nevada. This casino has 219 slots and 4 table game, as well as a bar and fine-dining restaurant and a cafeteria, along with approximately 300 parking spaces. The Grand Lodge Casino, which features 269 slot machines, 17 table games and is part of the Hyatt Regency Lake Tahoe Resort Spa and Casino, Incline Village. Full House Resorts, Inc. is located in Las Vegas, Nevada.

NASDAQ ended the session with Full House Resorts dropping 14.64% to $5.19 on Friday, after two successive sessions in a row of losses. NASDAQ jumped 0.9% to $11,127.84, after four successive sessions in a row of losses, on what was a somewhat positive trend trading session today.

Volume

Today’s last reported volume for Full House Resorts is 1758590 which is 508.21% above its average volume of 289142.

Full House Resorts’s last close was $6.08, 51.63% below its 52-week high of $12.57.

Full House Resorts’s Sales

Full House Resorts’s sales growth is a negative 1.4% for the current quarter and 6.6% for the next. The company’s growth estimates for the present quarter and the next is a negative 93.3% and a negative 92.3%, respectively.

Full House Resorts’s Revenue

Year-on-year quarterly revenue growth grew by 13.1%, now sitting on 180.16M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Full House Resorts’s stock is considered to be overbought (>=80).

Full House Resorts’s Stock Yearly Top and Bottom Value

Full House Resorts’s stock is valued at $5.19 at 17:33 EST, below its 52-week low of $5.27.

Full House Resorts’s Moving Average

Full House Resorts’s value is way below its 50-day moving average of $7.51 and way under its 200-day moving average of $9.31.

More news about Full House Resorts.

7. East Stone Acquisition Corporation (ESSCR) – -12.5%

NASDAQ ended the session with East Stone Acquisition Corporation dropping 12.5% to $0.14 on Friday, after five consecutive sessions in a row of losses. NASDAQ rose 0.9% to $11,127.84, after four consecutive sessions in a row of losses, on what was a somewhat up trend exchanging session today.

East Stone Acquisition Corporation’s last close was $0.14, 6.67% below its 52-week high of $0.15.

East Stone Acquisition Corporation’s Stock Yearly Top and Bottom Value

East Stone Acquisition Corporation’s stock is valued at $0.14 at 17:33 EST, below its 52-week low of $0.14.

More news about East Stone Acquisition Corporation.

8. ESSA Pharma (EPIX) – -9.48%

ESSA Pharma Inc. is a pharmaceutical company in clinical stages. It focuses its efforts on the development of novel therapies and other treatments for prostate cancer. EPI-7386 is an oral candidate being developed by the company. It’s currently in Phase 1 clinical trials for patients suffering from metastatic castration resistant prostate cancer. It has agreements with Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc. ESSA Pharma Inc. is a Canadian company that was established in 2009.

NASDAQ ended the session with ESSA Pharma dropping 9.48% to $3.15 on Friday, after five consecutive sessions in a row of losses. NASDAQ rose 0.9% to $11,127.84, after four sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Volume

Today’s last reported volume for ESSA Pharma is 143469 which is 24.91% below its average volume of 191088.

ESSA Pharma’s last close was $3.15, 89.39% under its 52-week high of $29.70.

The company’s growth estimates for the ongoing quarter and the next is a negative 28.6% and a negative 50%, respectively.

ESSA Pharma’s Stock Yearly Top and Bottom Value

ESSA Pharma’s stock is valued at $3.15 at 17:33 EST, way under its 52-week high of $29.70 and above its 52-week low of $3.13.

ESSA Pharma’s Moving Average

ESSA Pharma’s worth is way under its 50-day moving average of $5.18 and way below its 200-day moving average of $8.53.

More news about ESSA Pharma.

9. Amkor Technology (AMKR) – -9.35%

Amkor Technology, Inc. offers outsourced semiconductor packaging services and testing in the United States as well as internationally. It offers turnkey packaging services and testing services including wafer probes and wafer back-grinds for semiconductor wafers. The company’s packaging uses wirebond, flipchip, copper clip and other interconnect technology. It also offers semiconductor testing services such as wafer-level and final tests, flip chip scale packaging products that can be used in smartphones and tablets; flip chips stacked chip scale products that stack memory and are used as applications processors on mobile devices; and flipchip ball grid array products to support various networking, storage and computing applications. It also offers wafer level CSP packages for power management, sensor, codescs and specialty silicon, as well as wafer-level fan out packages that are used in ICs. Further, the company provides lead frame packages that are used in electronic devices for low to medium pin count applications; substrate-based wirebond packages, which are used to connect a die to a substrate; micro-electro-mechanical systems (MEMS) packages that are miniaturized mechanical and electro-mechanical devices; and advanced system-in-package modules, which are used in radio frequency and front end modules, basebands, connectivity, fingerprint sensors, display and touch screen drivers, sensors and MEMS, and NAND memory and solid state drives. The company serves mainly integrated device makers, fabless semiconductor manufacturers, original equipment producers, and contract findries. Amkor Technology, Inc., was established in 1968. It is located in Tempe, Arizona.

NASDAQ ended the session with Amkor Technology dropping 9.35% to $15.36 on Friday, following the last session’s upward trend. NASDAQ rose 0.9% to $11,127.84, after four consecutive sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for Amkor Technology is 955349 which is 1.47% below its average volume of 969657.

Amkor Technology’s last close was $16.95, 42.54% below its 52-week high of $29.50.

The company’s growth estimates for the current quarter and the next is 26.3% and 61.5%, respectively.

Amkor Technology’s Revenue

Year-on-year quarterly revenue growth grew by 20.4%, now sitting on 6.41B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Amkor Technology’s stock is considered to be overbought (>=80).

Amkor Technology’s Stock Yearly Top and Bottom Value

Amkor Technology’s stock is valued at $15.36 at 17:33 EST, below its 52-week low of $16.26.

Amkor Technology’s Moving Average

Amkor Technology’s worth is way under its 50-day moving average of $19.02 and way under its 200-day moving average of $22.18.

More news about Amkor Technology.

10. Dell (DELL) – -7.89%

Dell Technologies Inc. develops and markets IT hardware and software worldwide. The company operates in three divisions: Infrastructure Solutions Group, Client Solutions Group (CSG), or VMware. It offers traditional and next-generation storage solutions, as well rack, blade tower and hyperscale server options. The company also provides networking services and products that enable customers to modernize and transform their infrastructures. It can mobilize end-user experience and enhance business processes. CSG offers workstations and notebooks as well as displays, projectors and attached software. It also provides support, deployment and configuration services. Customers can rely on the VMware segment to address their IT needs, such as accelerating cloud adoption, modernizing applications, creating digital workplaces and improving security. Customers can digitally transform their business operations with this segment. It prepares their infrastructure and applications for changing business requirements. Customers can also benefit from the cloud-native platform, which makes IT development and operations easier. The company also provides information security and cybersecurity solutions; cloud software and infrastructure-as-a-service solutions that enable customers to migrate, run, and manage mission-critical applications in cloud-based IT environments; cloud-based integration services; and financial services. The former name of the company was Denali Holding Inc., but it changed its name in August 2016 to Dell Technologies Inc. Dell Technologies Inc. was established in 1984. It is located in Round Rock Texas.

NYSE ended the session with Dell falling 7.89% to $42.56 on Friday while NYSE rose 1.03% to $14,636.76.

Volume

Today’s last reported volume for Dell is 5204910 which is 11.51% above its average volume of 4667520.

Dell’s last close was $46.21, 24.91% under its 52-week high of $61.54.

Dell’s Sales

Dell’s sales growth is 2.5% for the ongoing quarter and a decline by 1.4% for the next. The company’s growth estimates for the present quarter and the next is a negative 34.3% and a negative 32.1%, respectively.

Dell’s Revenue

Year-on-year quarterly revenue growth grew by 7.2%, now sitting on 101.2B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Dell’s stock is considered to be overbought (>=80).

Dell’s Stock Yearly Top and Bottom Value

Dell’s stock is valued at $42.56 at 17:33 EST, way below its 52-week high of $61.54 and way above its 52-week low of $38.33.

Dell’s Moving Average

Dell’s value is below its 50-day moving average of $47.05 and way under its 200-day moving average of $52.97.

More news about Dell.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here